We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...
Calvin Sandra, the Senior Vice President and Chief Accounting Officer at Travere Therapeutics, Inc. (NASDAQ:TVTX), executed a series of transactions involving the company's common stock. The ...
The event featured not only Austin Laurette, who is "the unbreakable boy," but also some of the stars of the movie, Zachary ...
Its architect's daughter has cystic fibrosis—and benefits from a "miracle drug" backed by an agency he's attacking.
A Northland woman who suffered life-threatening dehydration was shocked to find she was fighting a Victorian-era disease: ...
Charleigh Pollock, 9, is being treated for a terminal neurological disorder known as Batten disease with twice-monthly infusions of a drug that costs about $1 million per year.
One in 10 Americans live with a rare disease, which often lacks effective treatments. Such is the case for PIGA-CDG, an ultra ...
To know Bentley Shelton is to love him. “He brings light to everybody that meets him,” said Brittany Shelton, Bentley’s mom. “He always ...
GlobalData on MSN19h
Travere takes rare disease kidney drug to FDA despite failed trialTravere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.
Tuesday, the agency signed off on SpringWorks’ Gomekli (mirdametinib) as a treatment for the rare genetic disorder ...
Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback